- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05765253
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
March 7, 2024 updated by: Argon Medical Devices
A Prospective, Multicenter, Randomized Study Evaluating Portal Vein Access Sets During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedures
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure.
The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.
Study Overview
Status
Terminated
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Danyel C Carr, MS
- Phone Number: 4697311421
- Email: Danyel.Carr@argonmedical.com
Study Contact Backup
- Name: Brent McClean
- Email: Brent.McClean@argonmedical.com
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
New York
-
New York, New York, United States, 10032
- New York Presbyterian - Columbia University Medical Center
-
Contact:
- Ramona Jayasena
- Email: rj2002@cumc.columbia.edu
-
Principal Investigator:
- Venkatesh Krishnasamy, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
Principal Investigator:
- Clayton Commander, MD
-
Contact:
- Desma Jones
- Email: desma_jones@med.unc.edu
-
Sub-Investigator:
- Hyeon Yu, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥ 18 years of age at the time of the TIPS procedure
- TIPS procedure initiated for refractory variceal bleeding, refractory ascites and/or hydrothorax
- Willing and able to provide written informed consent and HIPAA (Health Insurance Portability and Accountability Act) authorization
- Willing and able to comply with the study procedures and follow up schedule
Exclusion Criteria:
- Known active malignancy
- MELD score ≥ 18 at time of screening
- History of polycystic liver disease
- Active bleeding from any source
- Pulmonary hypertension, heart failure, severe tricuspid valve dysfunction, right to left cardiopulmonary shunt
- Chronic, occlusive portal vein thrombosis or complete portal vein thrombosis of the main or target portal vein on prior CT examination
- Active or uncontrolled hepatic encephalopathy
- Systemic infection/sepsis
- Biliary obstruction
- Uncorrectable coagulopathy
- Any diminutive or partially thrombosed right portal vein
- Hepatic vein thrombosis (i.e., no Budd-Chiari syndrome)
- Known sensitivity to contrast or serious contrast reaction such as anaphylaxis
- Pregnant women or women who are planning to become pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TIPS with Scorpion Portal Vein Access Kit
Scorpion or Scorpion X access set
|
Portal Vein Access with Scorpion or Scorpion X set
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
|
Active Comparator: TIPS with Cook Transjugular Liver Access Set
Ring or Rosch-Uchida access set
|
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Portal Vein Access with Ring or Rosch-Uchida set
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedural Success
Time Frame: Index Procedure
|
Creation of the parenchymal tract between the hepatic vein and an intrahepatic branch of the portal vein confirmed by portogram (CO2/contrast).
|
Index Procedure
|
Composite of Major Complications
Time Frame: Through 30 days post-TIPS procedure
|
Major complications associated with the procedure or study device and defined as complications resulting in an unplanned increase in the level of care, prolonged hospitalization, permanent adverse sequelae, or death.
|
Through 30 days post-TIPS procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: Index Procedure
|
Creation of a shunt (stent bridging) between the portal and systemic veins.
|
Index Procedure
|
Number of Needle Passes
Time Frame: Index Procedure
|
Count of needle throws between the hepatic and portal vein to create the parenchymal tract.
|
Index Procedure
|
Procedure Duration
Time Frame: Index Procedure
|
Interval (in minutes) from first jugular access for TIPS creation to removal of catheters from the patient.
|
Index Procedure
|
Fluoroscopy Time
Time Frame: Index Procedure
|
Measured in minutes
|
Index Procedure
|
Device-Related Complications
Time Frame: Through 30 days post-TIPS procedure
|
Incidence of complications related to the device as judged by the Investigator
|
Through 30 days post-TIPS procedure
|
Portal Vein Access (PVA) time
Time Frame: Index Procedure
|
Time (in minutes) from the first forward motion of the needle to confirmation of portal vein access via portogram.
|
Index Procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Venkatesh P. Krishnasamy, MD, New York Presbyterian - Columbia University Medical Center
- Study Director: Danyel C Carr, MS, Argon Medical Devices
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2023
Primary Completion (Actual)
October 16, 2023
Study Completion (Actual)
November 19, 2023
Study Registration Dates
First Submitted
March 1, 2023
First Submitted That Met QC Criteria
March 1, 2023
First Posted (Actual)
March 13, 2023
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCPVA01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Johannes Gutenberg University MainzUniversity of JenaCompletedNon-alcoholic Fatty Liver Disease | Fatty Liver, NonalcoholicGermany
-
The Cleveland ClinicCompleted
-
Hadassah Medical OrganizationUnknown
Clinical Trials on Scorpion Portal Vein Access Kit
-
Hospices Civils de LyonCompletedPacemaker | Implantable Cardioverter-defibrillatorFrance
-
Karolinska University HospitalRecruiting
-
The Christie NHS Foundation TrustManchester University NHS Foundation TrustCompleted
-
AC Camargo Cancer CenterCompletedCancer | Catheter ComplicationsBrazil
-
Seoul National University HospitalCompletedPancreatic Head Cancer Patients Who Underwent Surgery After Neoadjuvant Treatment
-
Royal Free Hospital NHS Foundation TrustUnknownNeuroendocrine Tumors | Pancreas Neoplasm
-
Castilla-La Mancha Health ServiceUnknownComplication | Defibrillators | Pacemakers | Pacemaker Electrode Lead FractureSpain
-
Institut Paoli-CalmettesRecruitingCancer of PancreasFrance
-
Corporacion Parc TauliWithdrawnCirrhosis | Hepatic Vein Thrombosis
-
IRCCS San RaffaeleRecruitingEUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients (EUPhORIC)Pancreatic Cancer | Pancreatic AdenocarcinomaItaly